The Discovery of GHK-Cu: How a Blood Plasma Fraction Led to One of the Most-Studied Peptides

For laboratory research use only. This article is a history-and-mechanism summary of publicly available literature on GHK-Cu, provided for reference. It is not medical, veterinary, cosmetic, or dosing guidance and makes no health, therapeutic, or outcome claims. Nothing described here is for human or animal use.

Most peptides in a research catalogue were designed. GHK-Cu was found — isolated from human blood plasma in 1973 by a biochemist who was not looking for a peptide at all. The route from an anomalous liver-cell experiment to one of the most-studied short peptides in the literature is worth following carefully, because the original observation still shapes how every subsequent study is framed.

1. The origin: how GHK-Cu was discovered

Pickart’s liver-cell observation

Loren Pickart was working at the University of California, San Francisco on the ageing of human liver cells. He observed that when aged hepatocytes were exposed to blood plasma from younger donors, the older cells resumed synthesising proteins they had stopped producing. The reciprocal experiment — young cells in older plasma — showed declining function.

The hypothesis that followed was straightforward and hard to test: some specific factor present in younger plasma was diminished with age.

Fractionating the albumin fraction

Finding it meant separating human plasma into fractions and testing each. The activity localised to the albumin fraction — albumin being the most abundant plasma protein and a carrier for hormones, metals, and small molecules. Within that fraction Pickart isolated a tripeptide with a strong affinity for copper: glycyl-L-histidyl-L-lysine. Bound to copper, it is the GHK-Cu complex.

That single isolation set up five decades of subsequent work, and it explains why the peptide is described as naturally occurring rather than engineered.

2. The molecule and why copper

The role described for GHK is copper chelation. Copper is a required cofactor for a number of enzymes:

• Energy metabolism — cytochrome c oxidase, essential to ATP generation.
• Antioxidant systems — superoxide dismutase (SOD).
• Matrix cross-linking — lysyl oxidase, which cross-links collagen and elastin and gives tissue its tensile properties.

Free copper, however, is redox-active and generates oxidative damage. Biology therefore transports copper bound rather than free, and GHK is one of the ligands that does it: it binds the ion, damps its reactivity, and releases it to cellular copper transporters at the point of uptake. The coordination chemistry behind that — the square-planar Cu(II) complex and the intermediate binding affinity that makes release possible — is covered in our chemistry-level explanation of the copper–peptide complex, and the naming conventions in what a tripeptide is.

What the complex is reported to do at the cell

The described sequence in the mechanism literature runs: the complex binds cell-surface receptors, is internalised, and the peptide is released intracellularly, where reported effects include upregulation of repair-associated gene expression, increased production of growth factors including TGF-β, VEGF and IGF-1, and increased synthesis of matrix components — collagen, elastin, fibronectin and glycosaminoglycans.

3. Why plasma GHK-Cu declines with age

Published figures describe a substantial fall in plasma concentration across a normal lifespan: roughly 200 ng/mL around age 20, roughly 80 ng/mL by age 60. That decline is the observation the field was built on, and it is worth stating precisely what it is and is not. It is a measured correlation between age and plasma concentration. It is not, on its own, evidence of causation in either direction, and the literature that follows from it is largely an attempt to establish which way the arrow points.

4. Gene expression: the breadth of the mechanism

For years the mechanism was known to work without the scope being known. Genomic profiling changed that. Work using the Broad Institute’s Connectivity Map — a database mapping how molecules affect human gene expression — reported that GHK modulates the expression of approximately 4,000 human genes.

This is the reason a three-residue peptide turns up across so many unrelated model systems. It is also the reason findings in one system should not be read as predicting another: a shared upstream mechanism is not a transferable result.

5. Wound-repair models

Long before it became a cosmetic ingredient, GHK-Cu was studied in tissue-repair models, and that literature remains the most developed. Repair proceeds in phases, and the reported involvement differs at each:

The remodelling-phase behaviour is the distinctive one. Degradation of disorganised matrix and synthesis of new, aligned matrix are reported as concurrent rather than sequential — which is the mechanism cited whenever scar-model work is discussed. Our review of GHK-Cu findings by application area takes the model systems one at a time.

6. Matrix synthesis in dermal models

In dermal-model work the reported readouts are matrix proteins: Type I and Type III collagen, elastin, and glycosaminoglycans — the water-binding molecules, hyaluronic acid among them, that account for matrix hydration. Studies comparing GHK-Cu against retinoic acid and ascorbic acid on collagen-synthesis endpoints exist, but they differ in preparation, concentration and endpoint definition, so the honest reading is that they examine different pathways rather than that one is superior. Cross-study comparison in this corpus is harder than it is usually presented.

7. Follicle models

Follicle research opened after animals treated in wound studies were observed to grow hair around the injury site. Reported findings include enlargement of miniaturised follicles, longer anagen-phase duration through action on dermal papilla cells, increased perifollicular vascularisation, and in some studies local inhibition of 5-alpha reductase. This is a smaller and more heterogeneous literature than the dermal work.

8. Naturally occurring versus engineered peptides

GHK-Cu is often contrasted with engineered peptide analogues, and the contrast is real but narrower than usually stated. GHK-Cu is identical in sequence to an endogenous plasma molecule, and its reported mechanism is broad — gene-expression modulation across many pathways at once. Engineered analogues are typically designed against a single pathway, which makes them easier to study and their results easier to interpret. Breadth and specificity are trade-offs in study design, not a ranking. Blended research material such as KLOW 80mg pairs GHK-Cu with TB-500 for exactly that reason — the two are examined for different steps.

9. What the discovery story is good for

The value of the 1973 work is not that it found a “youth factor”. It is that it identified a specific, characterisable molecule behind a diffuse observation, and made it possible to test rather than speculate. Fifty years on, the corpus is large, uneven in quality, and still concentrated in preclinical model systems.

Handling and verification

GHK-Cu ships as lyophilized powder and is reconstituted with bacteriostatic water, swirled rather than shaken. The copper complex is sensitive to pH and to competing chelators, so storage conditions matter more than they do for an unmetallated peptide. Confirm identity and purity against the certificate for the material in hand before comparing anything to published literature — third-party testing records are in our COA archive, and how to spot a fake peptide COA covers what a trustworthy certificate contains.

For laboratory and research use only. Not for human consumption. Nothing here is intended for human or animal use. All materials referenced are supplied strictly for in-vitro and other controlled preclinical research by qualified professionals and are third-party tested for identity and purity.